Neuroprotective effects of prostaglandin analogues on retinal ganglion cell death independent of intraocular pressure reduction

Experimental Eye Research

Volumn 93, Issue 3, 2011, Pages 265-270

  Yamagishi, Reiko ^a   Aihara, Makoto ^a   Araie, Makoto ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Glutamate; Neuroprotection; Prostaglandin; Retinal ganglion cell

Indexed keywords

BIMATOPROST; GLUTAMIC ACID; LATANOPROST; PROSTAGLANDIN F2 ALPHA; TAFLUPROST; TRAVOPROST; UNOPROSTONE;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DEATH; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; HYPOXIA; INTRAOCULAR PRESSURE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; RETINA GANGLION CELL; SURVIVAL RATE;

ANIMALS; ANIMALS, NEWBORN; ANTIHYPERTENSIVE AGENTS; APOPTOSIS; CELL HYPOXIA; CELL SURVIVAL; CELLS, CULTURED; GLUTAMIC ACID; INTRAOCULAR PRESSURE; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; PROSTAGLANDINS, SYNTHETIC; RATS; RATS, WISTAR; RETINAL GANGLION CELLS;

EID: 80054913988     PISSN: 00144835     EISSN: 10960007     Source Type: Journal    
DOI: 10.1016/j.exer.2011.06.022     Document Type: Article

References (39)

1. Abe T., Kunz A., Shimamura M., Zhou P., Anrather J., Iadecola C. The neuroprotective effect of prostaglandin E2 EP1 receptor inhibition has a wide therapeutic window, is sustained in time and is not sexually dimorphic. J. Cereb. Blood Flow Metab. 2009, 29:66-72.
2. Ahmad A.S., Zhuang H., Echeverria V., Dore S. Stimulation of prostaglandin EP2 receptors prevents NMDA-induced excitotoxicity. J. Neurotrauma 2006, 23:1895-1903.
3. Aihara M. Clinical appraisal of tafluprost in the reduction of elevated intraocular pressure (IOP) in open-angle glaucoma and ocular hypertension. Clin. Ophthalmol. 2010, 4:163-170.
4. Akaishi T., Kurashima H., Odani-Kawabata N., Ishida N., Nakamura M. Effects of repeated administrations of tafluprost, latanoprost, and travoprost on optic nerve head blood flow in conscious normal rabbits. J. Ocul. Pharmacol. Ther. 2010, 26:181-186.
5. Alagoz G., Gurel K., Bayer A., Serin D., Celebi S., Kukner S. A comparative study of bimatoprost and travoprost: effect on intraocular pressure and ocular circulation in newly diagnosed glaucoma patients. Ophthalmologica 2008, 222:88-95.
6. Aptel F., Cucherat M., Denis P. Efficacy and tolerability of prostaglandin analogs: a meta-analysis of randomized controlled clinical trials. J. Glaucoma 2008, 17:667-673.
7. Bean G.W., Camras C.B. Commercially available prostaglandin analogs for the reduction of intraocular pressure: similarities and differences. Surv. Ophthalmol. 2008, 53(Suppl. 1):S69-S84.
8. Bilak M., Wu L., Wang Q., Haughey N., Conant K., St Hillaire C., Andreasson K. PGE2 receptors rescue motor neurons in a model of amyotrophic lateral sclerosis. Ann. Neurol. 2004, 56:240-248.
9. Cantor L.B., Hoop J., Wudunn D., Yung C.W., Catoira Y., Valluri S., Cortes A., Acheampong A., Woodward D.F., Wheeler L.A. Levels of bimatoprost acid in the aqueous humour after bimatoprost treatment of patients with cataract. Br. J. Ophthalmol. 2007, 91:629-632.
10. Carlson N.G., Rojas M.A., Black J.D., Redd J.W., Hille J., Hill K.E., Rose J.W. Microglial inhibition of neuroprotection by antagonists of the EP1 prostaglandin E2 receptor. J. Neuroinflammation 2009, 6:5.
11. Choi S.H., Aid S., Bosetti F. The distinct roles of cyclooxygenase-1 and -2 in neuroinflammation: implications for translational research. Trends Pharmacol. Sci. 2009, 30:174-181.
12. Drago F., Valzelli S., Emmi I., Marino A., Scalia C.C., Marino V. Latanoprost exerts neuroprotective activity in vitro and in vivo. Exp. Eye Res. 2001, 72:479-486.
13. Echeverria V., Clerman A., Dore S. Stimulation of PGE receptors EP2 and EP4 protects cultured neurons against oxidative stress and cell death following beta-amyloid exposure. Eur. J. Neurosci. 2005, 22:2199-2206.
14. Emre S., Gul M., Ates B., Esrefoglu M., Koc B., Erdogan A., Yesilada E. Comparison of the protective effects of prostaglandin analogues in the ischemia and reperfusion model of rabbit eyes. Exp. Anim. 2009, 58:505-513.
15. Hernandez M., Urcola J.H., Vecino E. Retinal ganglion cell neuroprotection in a rat model of glaucoma following brimonidine, latanoprost or combined treatments. Exp. Eye Res. 2008, 86:798-806.
16. Holmstrom S., Buchholz P., Walt J., Wickstrom J., Aagren M. Analytic review of bimatoprost, latanoprost and travoprost in primary open angle glaucoma. Curr. Med. Res. Opin. 2005, 21:1875-1883.
17. Hutchinson A.J., Chou C.L., Israel D.D., Xu W., Regan J.W. Activation of EP2 prostanoid receptors in human glial cell lines stimulates the secretion of BDNF. Neurochem. Int. 2009, 54:439-446.
18. Inan U.U., Ermis S.S., Orman A., Onrat E., Yucel A., Ozturk F., Asagidag A., Celik A. The comparative cardiovascular, pulmonary, ocular blood flow, and ocular hypotensive effects of topical travoprost, bimatoprost, brimonidine, and betaxolol. J. Ocul. Pharmacol. Ther. 2004, 20:293-310.
19. Jiang J., Ganesh T., Du Y., Thepchatri P., Rojas A., Lewis I., Kurtkaya S., Li L., Qui M., Serrano G., Shaw R., Sun A., Dingledine R. Neuroprotection by selective allosteric potentiators of the EP2 prostaglandin receptor. Proc. Natl. Acad. Sci. U S A. 2010, 107:2307-2312.
20. Kanamori A., Naka M., Fukuda M., Nakamura M., Negi A. Latanoprost protects rat retinal ganglion cells from apoptosis in vitro and in vivo. Exp. Eye Res. 2009, 88:535-541.
21. Koz O.G., Ozsoy A., Yarangumeli A., Kose S.K., Kural G. Comparison of the effects of travoprost, latanoprost and bimatoprost on ocular circulation: a 6-month clinical trial. Acta Ophthalmol. Scand. 2007, 85:838-843.
22. Kudo H., Nakazawa T., Shimura M., Takahashi H., Fuse N., Kashiwagi K., Tamai M. Neuroprotective effect of latanoprost on rat retinal ganglion cells. Graefes Arch. Clin. Exp. Ophthalmol. 2006, 244:1003-1009.
23. Kurashima H., Watabe H., Sato N., Abe S., Ishida N., Yoshitomi T. Effects of prostaglandin F(2alpha) analogues on endothelin-1-inducedimpairment of rabbit ocular blood flow: comparison among tafluprost, travoprost, and latanoprost. Exp. Eye Res 2010.
24. Liang Y., Woodward D.F., Guzman V.M., Li C., Scott D.F., Wang J.W., Wheeler L.A., Garst M.E., Landsverk K., Sachs G., Krauss A.H., Cornell C., Martos J., Pettit S., Fliri H. Identification and pharmacological characterization of the prostaglandin FP receptor and FP receptor variant complexes. Br. J. Pharmacol. 2008, 154:1079-1093.
25. Liu D., Wu L., Breyer R., Mattson M.P., Andreasson K. Neuroprotection by the PGE2 EP2 receptor in permanent focal cerebral ischemia. Ann. Neurol. 2005, 57:758-761.
26. McCullough L., Wu L., Haughey N., Liang X., Hand T., Wang Q., Breyer R.M., Andreasson K. Neuroprotective function of the PGE2 EP2 receptor in cerebral ischemia. J. Neurosci. 2004, 24:257-268.
27. Melamed S. Neuroprotective properties of a synthetic docosanoid, unoprostone isopropyl: clinical benefits in the treatment of glaucoma. Drugs Exp. Clin. Res. 2002, 28:63-73.
28. Mukuno H., Nakamura M., Kanamori A., Nagai A., Negi A., Seigel G. Unoprostone isopropyl rescues retinal progenitor cells from apoptosis in vitro. Curr. Eye Res. 2004, 29:457-464.
29. Nakanishi Y., Nakamura M., Mukuno H., Kanamori A., Seigel G.M., Negi A. Latanoprost rescues retinal neuro-glial cells from apoptosis by inhibiting caspase-3, which is mediated by p44/p42 mitogen-activated protein kinase. Exp. Eye Res. 2006, 83:1108-1117.
30. Otori Y., Wei J.Y., Barnstable C.J. Neurotoxic effects of low doses of glutamate on purified rat retinal ganglion cells. Invest. Ophthalmol. Vis. Sci. 1998, 39:972-981.
31. Sales K.J., Grant V., Jabbour H.N. Prostaglandin E2 and F2alpha activate the FP receptor and up-regulate cyclooxygenase-2 expression via the cyclic AMP response element. Mol. Cell Endocrinol. 2008, 285:51-61.
32. Schutte B., Nuydens R., Geerts H., Ramaekers F. Annexin V binding assay as a tool to measure apoptosis in differentiated neuronal cells. J. Neurosci. Methods 1998, 86:63-69.
33. Tezel G., Yang X. Caspase-independent component of retinal ganglion cell death, in vitro. Invest.Ophthalmol. Vis. Sci. 2004, 45:4049-4059.
34. Uchida S., Suzuki Y., Araie M., Kashiwagi K., Otori Y., Sakuragawa N. Factors secreted by human amniotic epithelial cells promote the survival of rat retinal ganglion cells. Neurosci. Lett. 2003, 341:1-4.
35. Van Bergen N.J., Wood J.P., Chidlow G., Trounce I.A., Casson R.J., Ju W.K., Weinreb R.N., Crowston J.G. Recharacterization of the RGC-5 retinal ganglion cell line. Invest. Ophthalmol. Vis. Sci. 2009, 50:4267-4272.
36. van der Valk R., Webers C.A., Schouten J.S., Zeegers M.P., Hendrikse F., Prins M.H. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology 2005, 112:1177-1185.
37. Vidal L., Diaz F., Villena A., Moreno M., Campos J.G., Perez de Vargas I. Reaction of Muller cells in an experimental rat model of increased intraocular pressure following timolol, latanoprost and brimonidine. Brain Res. Bull. 2010, 82:18-24.
38. Yamada H., Chen Y.N., Aihara M., Araie M. Neuroprotective effect of calcium channel blocker against retinal ganglion cell damage under hypoxia. Brain Res. 2006, 1071:75-80.
39. Zhou P., Qian L., Chou T., Iadecola C. Neuroprotection by PGE2 receptor EP1 inhibition involves the PTEN/AKT pathway. Neurobiol. Dis. 2008, 29:543-551.